J&J Cypher Stent Approval Includes Rapamune Label Change Monitoring
Executive Summary
Post-marketing commitments for Johnson & Johnson/ Cordis' Cypher sirolimus-eluting stent include close monitoring of labeling changes for Wyeth's sirolimus product Rapamune
You may also be interested in...
FDA Device Center Director Departs; Feigal Oversaw Approval Of Cypher Stent
CDRH Office of Device Evaluation Director Daniel Schultz, MD, will become acting director of FDA's device center May 1, replacing David Feigal, MD
FDA Device Center Director Departs; Feigal Oversaw Approval Of Cypher Stent
CDRH Office of Device Evaluation Director Daniel Schultz, MD, will become acting director of FDA's device center May 1, replacing David Feigal, MD
FDA Combo Approvals Could Follow Drug-Eluting Stent Template
FDA should use its approval of drug-eluting stents as the template for combination product approvals, attendees recommended at FDA's drug delivery workshop July 8 in Bethesda, Md